To include your compound in the COVID-19 Resource Center, submit it here.

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

With $40M series A, Sonoma aims to develop Treg-based cell therapies for autoimmune, neurodegenerative diseases

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative diseases.

Sonoma’s investor syndicate includes Lyell Immunopharma Inc., Arch Venture Partners, Milky Way Ventures and 8VC.

President and CEO Jeffrey Bluestone told BioCentury that while at the University of California San Francisco in the early 2000s, he became interested in Tregs and the role the cells play in how the immune system shuts itself down. After publishing a 2004 paper in the Journal

Read the full 967 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE